Fig. 1: In vitro potency of MEK and PI3K inhibitors against syngeneic tumor cell lines. | Nature Communications

Fig. 1: In vitro potency of MEK and PI3K inhibitors against syngeneic tumor cell lines.

From: Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy

Fig. 1

ATP-based assessment of tumor cell viability in presence of indicated concentrations of small molecule inhibitors. Relative cell viability normalized to medium control. Inhibitory concentration (IC) 50 values calculated with 4-parameter logistic curve fit with bottom constraint >0. Mean ± s.e.m, n = 3. a Representative dose–response curves of murine tumor cell lines. b Mean IC50 values for indicated murine tumor cell lines of three independent experiments. Each experiment comprises three biological replicates. Shading indicates level of inhibitor potency (red: < 200 nM = sensitive; orange: 200–1000 nM = moderate; light yellow: > 1000 nM = not sensitive). c Western Blot analyses of indicated murine tumor cell lines treated with 0.5 µM GDC-0623 for 1 h. Representative data shown from two technical replicates. d, e Ki67/PI-based cell cycle analyses of tumor cells treated with 1 µM GDC-0623 and respective quantification. Mean ± s.e.m, n = 3. Unpaired student t test (medium vs. GDC-0623 for each cell cycle phase; FDR (Q = 1%), two-stage step-up method of Benjamini, Krieger and Yuketieli). Significance levels are indicated by asterisks (*p ≤ 0.05; **p ≤ 0.01; *** p ≤ 0.001; ****p ≤ 0.0001).

Back to article page